38 results on '"Navellou JC"'
Search Results
2. Septic shock in a cohort of patients from the northeast of France: a preliminary epidemiological study, EPISS group
- Author
-
Quenot, J, Pavon, A, Binquet, C, Kara, F, Martinet, O, Navellou, JC, Barraud, D, Cousson, J, and Poussel, JF
- Published
- 2011
- Full Text
- View/download PDF
3. Predictive and prognostic factors of septic shock of nosocomial origin
- Author
-
Quenot, JP, primary, Pavon, A, additional, Binquet, C, additional, Kara, F, additional, Martinet, O, additional, Ganster, F, additional, Navellou, JC, additional, Castelain, V, additional, Barraud, D, additional, Cousson, J, additional, Poussel, JF, additional, Perez, P, additional, Kuteifan, K, additional, and Noirot, A, additional
- Published
- 2012
- Full Text
- View/download PDF
4. Plasma citrulline kinetics and prognostic value in the critically ill patient
- Author
-
Piton, G, primary, Cypriani, B, additional, Monnet, E, additional, Navellou, JC, additional, Manzon, C, additional, Barbot, O, additional, Carbonnel, F, additional, and Capellier, G, additional
- Published
- 2009
- Full Text
- View/download PDF
5. Infarctus rénal et sténoses aortiques: pas que l'artériosclérose
- Author
-
Navellou, JC, primary, Desmurs, H, additional, de Wazières, B, additional, Combes, J, additional, Kantelip, B, additional, Chocron, S, additional, and Dupond, JL, additional
- Published
- 1997
- Full Text
- View/download PDF
6. La myopathie des états critiques aigus: une cause de quadriplégie spontanément réversible
- Author
-
Desmurs, H, primary, Blasco, G, additional, Navellou, JC, additional, Duchenne, F, additional, de Wazières, B, additional, and Dupond, JL, additional
- Published
- 1997
- Full Text
- View/download PDF
7. Thrombotic thrombocytopenic purpura associated with severe acute pancreatitis in a context of decreased ADAMTS13 activity: a case report.
- Author
-
Piton G, Navellou JC, Morati P, Patry C, Carbonnel F, Capellier G, Piton, Gaël, Navellou, Jean Christophe, Morati, Pierre, Patry, Cyrille, Carbonnel, Franck, and Capellier, Gilles
- Published
- 2008
- Full Text
- View/download PDF
8. Comparison of different lateral flow assays on bronchoalveolar lavage fluid for invasive aspergillosis screening in non-hematological patients.
- Author
-
Devillers E, Scherer E, Navellou JC, Grenouillet F, Millon L, and Bellanger AP
- Subjects
- Humans, Prospective Studies, Male, Female, Middle Aged, Aged, Adult, Mass Screening methods, Sensitivity and Specificity, Immunoassay methods, Aged, 80 and over, Bronchoalveolar Lavage Fluid microbiology, Bronchoalveolar Lavage Fluid chemistry, Galactose analogs & derivatives, Antigens, Fungal analysis, Mannans analysis, Aspergillus fumigatus isolation & purification, Invasive Pulmonary Aspergillosis diagnosis, Invasive Pulmonary Aspergillosis microbiology
- Abstract
Several lateral flow assays (LFA) capable of detecting Aspergillus fumigatus in serum and broncho-alveolar lavage fluid (BALF) within the hour, thereby potentially accelerating the screening process, are now commercially available. We prospectively compared three LFA targeting A. fumigatus on BALF collected from non-surgical intensive care patients between June 2022 and February 2023. The three LFA tested were Sõna Aspergillus galactomannan LFA (Immy), Fungadia Aspergillus antigen (Gadia), and AspLFD (OLM Diagnostics). We compared the results of these LFA with those of the galactomannan (GM) Platelia Aspergillus enzyme immunoassay (Bio-Rad), culture on Sabouraud medium and Aspergillus qPCR. We tested 97 BALF samples from 92 patients. In total 84 BALF samples tested negative with all three LFA, and four BALF samples tested positive with the AspLFD assay only (OLM). Only one BALF sample tested positive with the three LFA. In addition, three BALF samples tested positive only with the GM Platelia immunoassay. Four diagnosis of probable invasive aspergillosis were retained for the 92 patients tested. This prospective series included very few positive samples. From a practical point of view, the LFA from OLM presented the simplest protocol for use., Competing Interests: Declaration of competing interest The authors have no conflict of interest to declare., (Copyright © 2024. Published by Elsevier Masson SAS.)
- Published
- 2024
- Full Text
- View/download PDF
9. Respiratory multiplex PCR and procalcitonin to reduce antibiotic exposure in severe SARS-CoV-2 pneumonia: a multicentre randomized controlled trial.
- Author
-
Fartoukh M, Nseir S, Mégarbane B, Cohen Y, Lafarge A, Contou D, Thille AW, Galerneau LM, Reizine F, Cour M, Klouche K, Navellou JC, Bitker L, Rousseau A, Tuffet S, Simon T, and Voiriot G
- Subjects
- Adult, Humans, SARS-CoV-2 genetics, Procalcitonin therapeutic use, Anti-Bacterial Agents therapeutic use, Multiplex Polymerase Chain Reaction, Treatment Outcome, COVID-19 Testing, COVID-19 diagnosis, Respiratory Tract Infections diagnosis, Respiratory Tract Infections drug therapy, Bacterial Infections drug therapy
- Abstract
Objectives: We aimed at assessing the efficacy and safety on antibiotic exposure of a strategy combining a respiratory multiplex PCR (mPCR) with enlarged panel and daily procalcitonin (PCT) measurements, as compared with a conventional strategy, in adult patients who were critically ill with laboratory-confirmed SARS-CoV-2 pneumonia., Methods: This multicentre, parallel-group, open-label, randomized controlled trial enrolled patients admitted to 13 intensive care units (ICUs) in France. Patients were assigned (1:1) to the control strategy, in which antibiotic streamlining remained at the discretion of the physicians, or interventional strategy, consisting of using mPCR and daily PCT measurements within the first 7 days of randomization to streamline initial antibiotic therapy, with antibiotic continuation encouraged when PCT was >1 ng/mL and discouraged if < 1 ng/mL or decreased by 80% from baseline. All patients underwent conventional microbiological tests and cultures. The primary end point was antibiotic-free days at day 28., Results: Between April 20th and November 23rd 2020, 194 patients were randomized, of whom 191 were retained in the intention-to-treat analysis. Respiratory bacterial co-infection was detected in 48.4% (45/93) and 21.4% (21/98) in the interventional and control group, respectively. The number of antibiotic-free days was 12.0 (0.0; 25.0) and 14.0 (0.0; 24.0) days, respectively (difference, -2.0, (95% CI, -10.6 to 6.6), p=0.89). Superinfection rates were high (51.6% and 48.5%, respectively). Mortality rates and ICU lengths of stay did not differ between groups., Discussion: In severe SARS-CoV-2 pneumonia, the mPCR/PCT algorithm strategy did not affect 28-day antibiotics exposure nor the major clinical outcomes, as compared with routine practice., (Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
10. Refractory invasive pulmonary aspergillosis due to Aspergillus flavus detected with the combination of two in-house Aspergillus qPCR.
- Author
-
Caillet A, Bellanger AP, Navellou JC, Daguindau E, Rocchi S, Scherer E, Berceanu A, and Millon L
- Subjects
- Humans, Female, Aspergillus flavus genetics, Aspergillus genetics, Mannans, Galactose, Aspergillus fumigatus, Invasive Pulmonary Aspergillosis diagnosis, Invasive Pulmonary Aspergillosis drug therapy, Invasive Pulmonary Aspergillosis microbiology, Aspergillosis diagnosis, Aspergillosis drug therapy, Leukemia, Myeloid, Acute complications
- Abstract
We present a case of probable invasive pulmonary aspergillosis due to Aspergillus flavus, in a female patient treated for an acute myeloid leukemia. Two weeks after an allogenic stem cell transplantation a probable invasive pulmonary aspergillosis was diagnosed based on thoracic imaging combined with positive galactomannan antigen and positive in-house mitochondrial Aspergillus qPCR in serum. Although an antifungal treatment was initiated, Aspergillus qPCR and galactomannan antigen remained positive in serum and worsening of the thoracic lesions was observed. The discordance between the negativity of the in-house ribosomal Aspergillus qPCR (specific to A. fumigatus) and the positivity of the in-house mitochondrial Aspergillus qPCR (targeting A. fumigatus and some other Aspergillus) allowed the suspicion of a thermophilic Aspergillus species that was not A. fumigatus. No strain was obtained in culture but the involvement of A. flavus was confirmed using a specific A. flavus qPCR. This case illustrated the usefulness of our original strategy combining two different in-house Aspergillus qPCRs, in addition to galactomannan assay, to diagnose invasive aspergillosis in hematology patients., Competing Interests: Declaration of Competing Interest The authors declare no conflict of interest., (Copyright © 2022 SFMM. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
11. Investigation of the value of precipitins in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients with a positive marker for Aspergillus species.
- Author
-
Bellanger AP, Lallemand S, Tumasyan Horikian A, Navellou JC, Barrera C, Rouzet A, Scherer E, Reboux G, Piton G, and Millon L
- Subjects
- Animals, Antigens, Fungal, Aspergillus, Aspergillus fumigatus, Biomarkers, Female, Male, Precipitins, Retrospective Studies, SARS-CoV-2, COVID-19 diagnosis, COVID-19 veterinary, Invasive Pulmonary Aspergillosis diagnosis, Invasive Pulmonary Aspergillosis veterinary
- Abstract
Although a high prevalence of COVID-19-associated pulmonary aspergillosis has been reported, it is still difficult to distinguish between colonization with Aspergillus fumigatus and infection. Concomitantly, similarities between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hypersensitivity pneumonitis were suggested. The objective of this study was to investigate retrospectively if precipitin assays targeting A. fumigatus could have been useful in the management of SARS-CoV-2 patients hospitalized in an Intensive Care Unit (ICU) in 2020. SARS-CoV-2 ICU patients were screened for Aspergillus co-infection using biomarkers (galactomannan antigen, qPCR) and culture of respiratory samples (tracheal aspirates and bronchoalveolar lavage). For all these patients, clinical data, ICU characteristics and microbial results were collected. Electrosyneresis assays were performed using commercial A. fumigatus somatic and metabolic antigens. ELISA were performed using in-house A. fumigatus purified antigen and recombinant antigens.Our study population consisted of 65 predominantly male patients, with a median ICU stay of 22 days, and a global survival rate of 62%. Thirty-five patients had at least one positive marker for Aspergillus species detection. The number of arcs obtained by electrosyneresis using the somatic A. fumigatus antigen was significantly higher for these 35 SARS-CoV-2 ICU patients (P 0.01, Welch's t-test). Our study showed that SARS-CoV-2 ICU patients with a positive marker for Aspergillus species detection more often presented precipitins towards A. fumigatus. Serology assays could be an additional tool to assess the clinical relevance of the Aspergillus species in respiratory samples of SARS-CoV-2 ICU patients., Lay Summary: This study showed retrospectively that precipitin assays, such as electrosyneresis, could be helpful to distinguish between colonization and infection with Aspergillus fumigatus during the management of severe acute respiratory syndrome Coronavirus-2 (SARS CoV-2) patients in an intensive care unit., (© The Author(s) 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.)
- Published
- 2022
- Full Text
- View/download PDF
12. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
- Author
-
Ader F, Peiffer-Smadja N, Poissy J, Bouscambert-Duchamp M, Belhadi D, Diallo A, Delmas C, Saillard J, Dechanet A, Mercier N, Dupont A, Alfaiate T, Lescure FX, Raffi F, Goehringer F, Kimmoun A, Jaureguiberry S, Reignier J, Nseir S, Danion F, Clere-Jehl R, Bouiller K, Navellou JC, Tolsma V, Cabié A, Dubost C, Courjon J, Leroy S, Mootien J, Gaci R, Mourvillier B, Faure E, Pourcher V, Gallien S, Launay O, Lacombe K, Lanoix JP, Makinson A, Martin-Blondel G, Bouadma L, Botelho-Nevers E, Gagneux-Brunon A, Epaulard O, Piroth L, Wallet F, Richard JC, Reuter J, Staub T, Lina B, Noret M, Andrejak C, Lê MP, Peytavin G, Hites M, Costagliola D, Yazdanpanah Y, Burdet C, and Mentré F
- Subjects
- Adult, Drug Combinations, Female, Humans, Male, Middle Aged, Treatment Outcome, Antiviral Agents therapeutic use, Hydroxychloroquine therapeutic use, Interferon beta-1a therapeutic use, Lopinavir therapeutic use, Ritonavir therapeutic use, COVID-19 Drug Treatment
- Abstract
Objectives: We evaluated the clinical, virological and safety outcomes of lopinavir/ritonavir, lopinavir/ritonavir-interferon (IFN)-β-1a, hydroxychloroquine or remdesivir in comparison to standard of care (control) in coronavirus 2019 disease (COVID-19) inpatients requiring oxygen and/or ventilatory support., Methods: We conducted a phase III multicentre, open-label, randomized 1:1:1:1:1, adaptive, controlled trial (DisCoVeRy), an add-on to the Solidarity trial (NCT04315948, EudraCT2020-000936-23). The primary outcome was the clinical status at day 15, measured by the WHO seven-point ordinal scale. Secondary outcomes included quantification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in respiratory specimens and pharmacokinetic and safety analyses. We report the results for the lopinavir/ritonavir-containing arms and for the hydroxychloroquine arm, trials of which were stopped prematurely., Results: The intention-to-treat population included 583 participants-lopinavir/ritonavir (n = 145), lopinavir/ritonavir-IFN-β-1a (n = 145), hydroxychloroquine (n = 145), control (n = 148)-among whom 418 (71.7%) were male, the median age was 63 years (IQR 54-71), and 211 (36.2%) had a severe disease. The day-15 clinical status was not improved with the investigational treatments: lopinavir/ritonavir versus control, adjusted odds ratio (aOR) 0.83, (95% confidence interval (CI) 0.55-1.26, p 0.39), lopinavir/ritonavir-IFN-β-1a versus control, aOR 0.69 (95%CI 0.45-1.04, p 0.08), and hydroxychloroquine versus control, aOR 0.93 (95%CI 0.62-1.41, p 0.75). No significant effect of investigational treatment was observed on SARS-CoV-2 clearance. Trough plasma concentrations of lopinavir and ritonavir were higher than those expected, while those of hydroxychloroquine were those expected with the dosing regimen. The occurrence of serious adverse events was significantly higher in participants allocated to the lopinavir/ritonavir-containing arms., Conclusion: In adults hospitalized for COVID-19, lopinavir/ritonavir, lopinavir/ritonavir-IFN-β-1a and hydroxychloroquine improved neither the clinical status at day 15 nor SARS-CoV-2 clearance in respiratory tract specimens., (Copyright © 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
13. Mixed mold infection with Aspergillus fumigatus and Rhizopus microsporus in a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) patient.
- Author
-
Bellanger AP, Navellou JC, Lepiller Q, Brion A, Brunel AS, Millon L, and Berceanu A
- Subjects
- Amphotericin B therapeutic use, Antifungal Agents therapeutic use, Aspergillus fumigatus isolation & purification, COVID-19 complications, Coinfection complications, Coinfection drug therapy, Fatal Outcome, Humans, Immunocompromised Host, Invasive Pulmonary Aspergillosis complications, Invasive Pulmonary Aspergillosis drug therapy, Male, Microbial Sensitivity Tests, Middle Aged, Mucormycosis complications, Mucormycosis drug therapy, Polymerase Chain Reaction methods, Rhizopus isolation & purification, SARS-CoV-2 isolation & purification, Viral Load, COVID-19 diagnosis, Coinfection diagnosis, Invasive Pulmonary Aspergillosis diagnosis, Mucormycosis diagnosis
- Published
- 2021
- Full Text
- View/download PDF
14. New clinical algorithm including fungal biomarkers to better diagnose probable invasive pulmonary aspergillosis in ICU.
- Author
-
Hamam J, Navellou JC, Bellanger AP, Bretagne S, Winiszewski H, Scherer E, Piton G, and Millon L
- Abstract
Background: The classification of invasive pulmonary aspergillosis (IPA) issued by the European Organization for the Research and Treatment of Cancer/Mycoses Study Group Education and Research Consortium (EORTC/MSGERC) is used for immunocompromised patients. An alternative algorithm adapted to the intensive care unit (ICU) population has been proposed (AspICU), but this algorithm did not include microbial biomarkers such as the galactomannan antigen and the Aspergillus quantitative PCR. The objective of the present pilot study was to evaluate a new algorithm that includes fungal biomarkers (BM-AspICU) for the diagnosis of probable IPA in an ICU population., Patients and Methods: Data from 35 patients with pathology-proven IPA according to European Organization for the Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSGERC)-2008 criteria were extracted from the French multicenter database of the Invasive Fungal Infections Surveillance Network (RESSIF). The patients were investigated according to the AspICU algorithm, and the BM-AspICU algorithm in analyzing the clinical, imaging, and biomarker data available in the records, without taking into account the pathology findings., Results: Eight patients had to be excluded because no imaging data were recorded in the database. Among the 27 proven IPAs with complete data, 16 would have been considered as putative IPA with the AspICU algorithm and 24 would have been considered as probable IPA using the new algorithm BM-AspICU. Seven out of the 8 patients with probable BM-AspICU IPA (and not classified with the AspICU algorithm) had no host factors and no Aspergillus-positive broncho-alveolar lavage fluid (BALF) culture. Three patients were non-classifiable with any of the two algorithms, because they did not have any microbial criteria during the course of the infection, and diagnosis of proven aspergillosis was done using autopsy samples., Conclusion: Inclusion of biomarkers could be effective to identify probable IPA in the ICU population. A prospective study is needed to validate the routine application of the BM-AspICU algorithm in the ICU population.
- Published
- 2021
- Full Text
- View/download PDF
15. Mucormycosis in intensive care unit: surgery is a major prognostic factor in patients with hematological malignancy.
- Author
-
Claustre J, Larcher R, Jouve T, Truche AS, Nseir S, Cadiet J, Zerbib Y, Lautrette A, Constantin JM, Charles PE, Daubin C, Coudroy R, Dellamonica J, Argaud L, Phelouzat P, Contou D, Pocquet J, Voiriot G, Navellou JC, Lavagne P, Durand M, Cornet M, Schwebel C, and Terzi N
- Abstract
Background: Mucormycosis is an invasive fungal infection, with an increasing incidence especially in patients with hematological malignancies. Its prognosis is poor because of its high invasive power and its intrinsic low susceptibility to antifungal agents. We aimed to describe the epidemiology of mucormycosis in intensive care units (ICU) and evaluate the outcomes. We performed a retrospective multi-center study in 16 French ICUs between 2008 and 2017. We compared the patients who survived in ICU and the patients who did not to identify factors associated with ICU survival. Then, we focused on the subgroup of patients with hematological malignancies., Results: Mucormycosis was diagnosed in 74 patients during the study period. Among them, 60 patients (81%) were immunocompromised: 41 had hematological malignancies, 9 were solid organ transplant recipients, 31 received long-term steroids, 11 had diabetes, 24 had malnutrition. Only 21 patients survived to ICU stay (28.4%) with a median survival of 22 days (Q1-Q3 = 9-106) and a survival rate at day 28 and day 90, respectively, of 35.1% and 26.4%. Survivors were significantly younger (p = 0.001), with less frequently hematological malignancies (p = 0.02), and less malnutrition (p = 0.05). Median survival in patients with hematological malignancies (n = 41) was 15 days (Q1-Q3 = 5-23.5 days). In this subgroup, curative surgery was a major factor associated with survival in multivariate analysis (odds ratio = 0.71, [0.45-0.97], p < 0.001)., Conclusion: Overall prognosis of mucormycosis in ICU remains poor, especially in patients with hematological malignancies. In this subgroup of patients, a therapeutic strategy including curative surgery was the main factor associated with survival.
- Published
- 2020
- Full Text
- View/download PDF
16. The pharmacokinetic challenge of treating invasive aspergillosis complicating severe influenzae assisted by extracorporeal membrane oxygenation.
- Author
-
Winiszewski H, Rougny AC, Lagoutte-Renosi J, Millon L, Capellier G, Navellou JC, Piton G, and Clairet AL
- Subjects
- Antifungal Agents therapeutic use, Aspergillus fumigatus drug effects, Aspergillus fumigatus pathogenicity, Bronchopulmonary Sequestration complications, Extracorporeal Membrane Oxygenation trends, Humans, Invasive Fungal Infections drug therapy, Male, Middle Aged, Nitriles therapeutic use, Pyridines therapeutic use, Triazoles therapeutic use, Voriconazole therapeutic use, Aspergillosis drug therapy, Extracorporeal Membrane Oxygenation methods, Influenza, Human drug therapy
- Published
- 2018
- Full Text
- View/download PDF
17. Development of a quantitative PCR detecting Cunninghamella bertholletiae to help in diagnosing this rare and aggressive mucormycosis.
- Author
-
Bellanger AP, Berceanu A, Rocchi S, Valot B, Fontan J, Chauchet A, Belin N, Scherer E, Deconinck E, Navellou JC, and Millon L
- Subjects
- Antifungal Agents therapeutic use, Fatal Outcome, Humans, Immunocompromised Host, Leukemia, Lymphocytic, Chronic, B-Cell microbiology, Lung microbiology, Male, Cunninghamella isolation & purification, Mucormycosis diagnosis, Real-Time Polymerase Chain Reaction methods
- Abstract
Mucormycosis is an invasive mold infection, frequently fatal in immunocompromised patients. We report the case of a patient with chronic lymphocytic leukemia admitted to the hematology unit for febrile aplasia. Pulmonary lesions suggesting a fungal infection expanded/increased despite a combination of posaconazole and liposomal amphotericin B. The fungal biomarkers performed repeatedly were negative. At D65 after chemotherapy a bronchial biopsy was positive for Cunninghamella bertholletiae. The patient died despite appropriate antifungal management. A qPCR targeting Cunninghamella was developed a posteriori, and a retrospective analysis showed that a sample was positive more than 30 days before culture-based identification could be made.
- Published
- 2018
- Full Text
- View/download PDF
18. Daily use of extracorporeal CO 2 removal in a critical care unit: indications and results.
- Author
-
Winiszewski H, Aptel F, Belon F, Belin N, Chaignat C, Patry C, Clermont C, David E, Navellou JC, Labro G, Piton G, and Capellier G
- Abstract
Background: While outcome improvement with extracorporeal CO
2 removal (ECCO2 R) is not demonstrated, a strong pathophysiological rational supports its use in the setting of acute respiratory distress syndrome (ARDS) and COPD exacerbation. We aimed to describe our single-center experience of ECCO2 R indications and outcome., Methods: Patients treated with ECCO2 R in our medial ICU, from March 2014 to November 2017, were retrospectively enrolled. Primary end point was evolution of ventilator settings during the two first days following ECCO2 R start., Results: Thirty-three patients received ECCO2 R. Seventeen were managed with Hemolung®, 10 with Prismalung®, 4 with ILA®, and 2 with Cardiohelp®. Indications for ECCO2 R were mild or moderate ARDS ( n = 16), COPD exacerbation ( n = 11), or uncontrolled hypercapnia due to other causes ( n = 6). Four patients were not intubated at the time of ECCO2 R start. Median duration of ECCO2 R treatment was 7 days [5-10]. In ARDS patients, between baseline and day 2, median tidal volume and driving pressure decreased from 5.3 [4.4-5.9] mL/kg and 10 [8-15] to 3.8 [3.3-4.1] mL/kg and 9 [8-11], respectively. Prone positioning was performed in 10 of the 16 patients, without serious adverse event. In COPD patients, between baseline and day 2, median ventilation minute and PaCO2 decreased significantly from respectively 7.6 [6.6-8.7] L/min and 9.4 [8.4-10.1] kPa to 5.8 [4.9-6.2] L/min and 6 [5.3-6.8] kPa. Four out of 11 COPD patients were extubated while on ECCO2 R. Device thrombosis occurred in 5 patients (15%). Hemolysis was documented in 16 patients (48%). One patient died of intracranial hemorrhage, while on ECCO2 R. Twenty-four patients were discharged from ICU alive. Twenty-eight day mortality was 31% in ARDS, 9% in COPD patients, and 50% in other causes of refractory hypercapnic respiratory failure., Conclusion: ECCO2 R was useful to apply ultra-protective ventilation among ARDS patients and improved PaCO2 , pH, and minute ventilation in COPD patients., Competing Interests: According to French law, written inform consent is not required for a retropective case series. All patients (or proxy) admitted in our ICU are informed that medical data may be used for research. If they wish, they may refuse that (approved by an Ethic Committee on March 2013). In this clinical case, no opposition was expressed for using data for research.Pr Capellier has received lecture fees from Baxter and Alung. Prismalung® devices were provided by Baxter. The other authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.- Published
- 2018
- Full Text
- View/download PDF
19. Septic shock with round necrotic skin lesions.
- Author
-
Winiszewski H, Labro G, Navellou JC, and Piton G
- Subjects
- Humans, Necrosis complications, Shock, Septic complications, Skin Diseases complications
- Published
- 2018
- Full Text
- View/download PDF
20. Anti-N-Methyl-d-Aspartate Receptor Encephalitis in Adult Patients Requiring Intensive Care.
- Author
-
de Montmollin E, Demeret S, Brulé N, Conrad M, Dailler F, Lerolle N, Navellou JC, Schwebel C, Alves M, Cour M, Engrand N, Tonnelier JM, Maury E, Ruckly S, Picard G, Rogemond V, Magalhaes É, Sharshar T, Timsit JF, Honnorat J, and Sonneville R
- Subjects
- Administration, Intravenous, Adult, Age Distribution, Analysis of Variance, Anti-N-Methyl-D-Aspartate Receptor Encephalitis cerebrospinal fluid, Anti-N-Methyl-D-Aspartate Receptor Encephalitis therapy, Female, France, Humans, Immunoglobulins administration & dosage, Immunotherapy methods, Intensive Care Units, Male, Neuroimaging methods, Plasmapheresis methods, Prognosis, Receptors, N-Methyl-D-Aspartate immunology, Retrospective Studies, Secondary Prevention, Sex Distribution, Treatment Outcome, Young Adult, Anti-N-Methyl-D-Aspartate Receptor Encephalitis immunology, Brain physiopathology, Immunoglobulins therapeutic use, Steroids therapeutic use
- Abstract
Rationale: Encephalitis caused by anti-N-methyl-d-aspartate receptor (NMDAR) antibodies is the leading cause of immune-mediated encephalitis. There are limited data on intensive care unit (ICU) management of these patients., Objectives: To identify prognostic factors of good neurologic outcome in patients admitted to an ICU with anti-NMDAR encephalitis., Methods: This was an observational multicenter study of all consecutive adult patients diagnosed with anti-NMDAR encephalitis at the French National Reference Centre, admitted to an ICU between 2008 and 2014. The primary outcome was a good neurologic outcome at 6 months after ICU admission, defined by a modified Rankin Scale score of 0-2., Measurements and Main Results: Seventy-seven patients were included from 52 ICUs. First-line immunotherapy consisted of steroids (n = 61/74; 82%), intravenous immunoglobulins (n = 71/74; 96%), and plasmapheresis (n = 17/74; 23%). Forty-five (61%) patients received second-line immunotherapy (cyclophosphamide, rituximab, or both). At 6 months, 57% of patients had a good neurologic outcome. Independent factors of good neurologic outcome were early (≤8 d after ICU admission) immunotherapy (odds ratio, 16.16; 95% confidence interval, 3.32-78.64; for combined first-line immunotherapy with steroids and intravenous immunoglobulins vs. late immunotherapy), and a low white blood cell count on the first cerebrospinal examination (odds ratio, 9.83 for <5 vs. >50 cells/mm
3 ; 95% confidence interval, 1.07-90.65). Presence of nonneurologic organ failures at ICU admission and occurrence of status epilepticus during ICU stay were not associated with neurologic outcome., Conclusions: The prognosis of adult patients with anti-NMDAR encephalitis requiring intensive care is good, especially when immunotherapy is initiated early, advocating for prompt diagnosis and early aggressive treatment.- Published
- 2017
- Full Text
- View/download PDF
21. Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation.
- Author
-
Jullien V, Azoulay E, Schwebel C, Le Saux T, Charles PE, Cornet M, Souweine B, Klouche K, Jaber S, Trouillet JL, Bruneel F, Cour M, Cousson J, Meziani F, Gruson D, Paris A, Darmon M, Garrouste-Orgeas M, Navellou JC, Foucrier A, Allaouchiche B, Das V, Gangneux JP, Ruckly S, Wolff M, and Timsit JF
- Subjects
- Adult, Aged, Aged, 80 and over, Antifungal Agents administration & dosage, Candida drug effects, Echinocandins administration & dosage, Female, Humans, Intensive Care Units, Lipopeptides administration & dosage, Male, Micafungin, Microbial Sensitivity Tests, Middle Aged, Monte Carlo Method, Antifungal Agents pharmacokinetics, Antifungal Agents pharmacology, Candidemia drug therapy, Echinocandins pharmacokinetics, Echinocandins pharmacology, Lipopeptides pharmacokinetics, Lipopeptides pharmacology, Respiration, Artificial
- Abstract
Objectives: To identify the factors associated with the interindividual pharmacokinetic (PK) variability of micafungin and to evaluate the probability of reaching the previously determined PK/pharmacodynamic efficacy thresholds (AUC/MIC >5000 for non-parapsilosis Candida sp. and ≥285 for Candida parapsilosis) with the recommended 100 mg daily dose in ICU patients with sepsis and mechanical ventilation., Methods: One hundred patients were included and 436 concentrations were available for PK analysis performed with NONMEM software. PTA was determined by Monte Carlo simulations., Results: Micafungin obeyed a two-compartment model with first-order elimination from the central compartment. Mean parameter estimates (percentage interindividual variability) were 1.34 L/h (34%) for clearance (CL), 11.80 L (38%) and 7.68 L (39%) for central (Vc) and peripheral (Vp) distribution volumes, respectively, and 4.67 L/h (37%) for distribution clearance. CL, Vc and Vp increased by 14% when the albumin level was ≤25 g/L and CL decreased by 25% when SOFA score was ≥10. Body weight was related to CL, Vc and Vp by allometric models. PTA was ≥90% in Candida albicans and Candida glabrata infections, except when the MIC was ≥0.015 mg/L, and ranged between 0% and 40% for C. parapsilosis infections with MIC ≥0.5 mg/L., Conclusions: A possible increase in the dose should be evaluated for infections due to C. parapsilosis and for infections due to C. albicans and C. glabrata with MICs ≥0.015 mg/L., (© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2017
- Full Text
- View/download PDF
22. Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial.
- Author
-
Timsit JF, Azoulay E, Schwebel C, Charles PE, Cornet M, Souweine B, Klouche K, Jaber S, Trouillet JL, Bruneel F, Argaud L, Cousson J, Meziani F, Gruson D, Paris A, Darmon M, Garrouste-Orgeas M, Navellou JC, Foucrier A, Allaouchiche B, Das V, Gangneux JP, Ruckly S, Maubon D, Jullien V, and Wolff M
- Subjects
- Aged, Anti-Bacterial Agents therapeutic use, Candidiasis drug therapy, Candidiasis mortality, Critical Illness, Cross Infection microbiology, Disease-Free Survival, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Micafungin, Middle Aged, Time Factors, Antifungal Agents therapeutic use, Candidiasis, Invasive mortality, Candidiasis, Invasive prevention & control, Cross Infection drug therapy, Cross Infection mortality, Echinocandins therapeutic use, Lipopeptides therapeutic use, Multiple Organ Failure mortality
- Abstract
Importance: Although frequently used in treating intensive care unit (ICU) patients with sepsis, empirical antifungal therapy, initiated for suspected fungal infection, has not been shown to improve outcome., Objective: To determine whether empirical micafungin reduces invasive fungal infection (IFI)-free survival at day 28., Design, Setting, and Participants: Multicenter double-blind placebo-controlled study of 260 nonneutropenic, nontransplanted, critically ill patients with ICU-acquired sepsis, multiple Candida colonization, multiple organ failure, exposed to broad-spectrum antibacterial agents, and enrolled between July 2012 and February 2015 in 19 French ICUs., Interventions: Empirical treatment with micafungin (100 mg, once daily, for 14 days) (n = 131) vs placebo (n = 129)., Main Outcomes and Measures: The primary end point was survival without proven IFI 28 days after randomization. Key secondary end points included new proven fungal infections, survival at day 28 and day 90, organ failure, serum (1-3)-β-D-glucan level evolution, and incidence of ventilator-associated bacterial pneumonia., Results: Among 260 patients (mean age 63 years; 91 [35%] women), 251 (128, micafungin group; 123, placebo group) were included in the modified intent-to-treat analysis. Median values were 8 for Sequential Organ Failure Assessment (SOFA) score, 3 for number of Candida-colonized sites, and 99 pg/mL for level of (1-3)-β-D-glucan. On day 28, there were 82 (68%) patients in the micafungin group vs 79 (60.2%) in the placebo group who were alive and IFI free (hazard ratio [HR], 1.35 [95% CI, 0.87-2.08]). Results were similar among patients with a (1-3)-β-D-glucan level of greater than 80 pg/mL (n = 175; HR, 1.41 [95% CI, 0.85-2.33]). Day-28 IFI-free survival in patients with a high SOFA score (>8) was not significantly different when compared between the micafungin vs placebo groups (HR, 1.69 [95% CI, 0.96-2.94]). Use of empirical micafungin decreased the rate of new invasive fungal infection in 4 of 128 patients (3%) in the micafungin group vs placebo (15/123 patients [12%]) (P = .008)., Conclusions and Relevance: Among nonneutropenic critically ill patients with ICU-acquired sepsis, Candida species colonization at multiple sites, and multiple organ failure, empirical treatment with micafungin, compared with placebo, did not increase fungal infection-free survival at day 28., Trial Registration: clinicaltrials.gov Idenitfier: NCT01773876.
- Published
- 2016
- Full Text
- View/download PDF
23. Enterocyte Damage: A Piece in the Puzzle of Post-Cardiac Arrest Syndrome.
- Author
-
Piton G, Belin N, Barrot L, Belon F, Cypriani B, Navellou JC, and Capellier G
- Subjects
- Aged, Biomarkers blood, Citrulline blood, Fatty Acid-Binding Proteins blood, Female, Heart Arrest complications, Heart Arrest diagnosis, Humans, Intensive Care Units, Male, Middle Aged, Nervous System Diseases etiology, Prognosis, Prospective Studies, Enterocytes pathology, Heart Arrest pathology
- Abstract
Cardiac arrest is considered to be a cause of small bowel ischemia, but the consequences of cardiac arrest on the human small bowel have been rarely studied. Plasma citrulline concentration is a marker of functional enterocyte mass, and plasma intestinal fatty acid-binding protein (I-FABP) concentration is a marker of enterocyte damage. We aimed to measure enterocyte biomarkers after cardiac arrest and to study the prognostic value of biomarker abnormalities. This is a prospective, observational, single-center study of patients admitted to the intensive care unit (ICU) for cardiac arrest, evaluating plasma citrulline and I-FABP concentrations at admission and after 24 h and variables according to the Utstein criteria. Variables according to 28-day Cerebral Performance Category score of 1 to 2 (good neurological outcome) versus 3 to 5 (poor neurological outcome) were compared. Sixty-nine patients with cardiac arrest of both cardiac and hypoxic origin were included. At ICU admission, plasma citrulline concentration was low in 65% and plasma I-FABP was elevated in 82% of the patients. After 24 h, plasma citrulline was low in 82% and I-FABP was normal in 60% of the patients. Patients with a poor neurological outcome had a lower plasma citrulline concentration and a higher I-FABP concentration at ICU admission. By multivariate analysis, plasma citrulline levels of 13.1 μmol L or less and I-FABP more than 260 pg mL were independently associated with a poor neurological outcome (odds ratio, 21.9 [2.2-215], and odds ratio, 13.6 [1.4-129], respectively). Cardiac arrest resuscitation is associated with evidence of small bowel mucosal damage in most patients, with a short and intense I-FABP elevation at admission and a decrease in citrulline concentration during the first day. In this study, low plasma citrulline and high I-FABP concentrations at ICU admission were predictive of a poor neurological outcome. This study confirms that cardiac arrest is a model of small bowel mucosal ischemia and suggests that enterocyte damage is a piece in the puzzle of post-cardiac arrest syndrome.
- Published
- 2015
- Full Text
- View/download PDF
24. Acquisition of carbapenem-resistant Gram-negative bacilli in intensive care unit: predictors and molecular epidemiology.
- Author
-
Marchenay P, Blasco G, Navellou JC, Leroy J, Cholley P, Talon D, Bertrand X, and Gbaguidi-Haore H
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Molecular Epidemiology, Prospective Studies, Risk Factors, Carbapenems pharmacology, Gram-Negative Bacteria drug effects, Intensive Care Units, beta-Lactam Resistance
- Abstract
Objectives: We had for aim to determine the risk factors for acquiring carbapenem-intermediate or -resistant Gram-negative bacilli (CR-GNB) in an intensive care unit (ICU) and to identify the resistance mechanisms involved., Patients and Methods: We conducted an observational prospective cohort study during 6 months in medical and surgical ICUs of the Besançon Teaching Hospital. Patients with acquired CR-GNB were patients whose cultures (screening or diagnosis) became positive more than 48h after admission to the ICU. The risk factors for ICU-acquired CR-GNB were determined by multivariate logistic regression. CR-GNB isolates were typed by pulsed-field gel electrophoresis (PFGE) and screened for resistance mechanisms with phenotypic and genotypic tests., Results: Twenty-three of the 347 included patients had acquired a CR-GNB. The multivariate analysis revealed significant associations between this acquisition and the duration of previous treatments with piperacillin-tazobactam (adjusted odds ratio [aOR], 1.13, P=0.02) and aminoglycosides (aOR, 1.62; P=0.005), but not with carbapenems. The CR-GNB strains were identified as Pseudomonas aeruginosa (n=10), Stenotrophomonas maltophilia (n=7), and Enterobacter cloacae (n=6). No acquired carbapenemase-producing strain was identified. PFGE typing identified 1 multiple clone among P. aeruginosa isolates (4 patients), whereas for the other bacteria, all the strains were different., Conclusion: Our study results suggest that the strategy to prevent the emergence and spread of CR-GNB should not be limited to the sole restriction of carbapenem use in ICU settings., (Copyright © 2015 Elsevier Masson SAS. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
25. Long-term outcomes and cardiac surgery in critically ill patients with infective endocarditis.
- Author
-
Mirabel M, Sonneville R, Hajage D, Novy E, Tubach F, Vignon P, Perez P, Lavoué S, Kouatchet A, Pajot O, Mekontso-Dessap A, Tonnelier JM, Bollaert PE, Frat JP, Navellou JC, Hyvernat H, Hssain AA, Timsit JF, Megarbane B, Wolff M, and Trouillet JL
- Subjects
- Adolescent, Adult, Aged, Critical Illness, Cross-Sectional Studies, Emergency Treatment mortality, Emergency Treatment statistics & numerical data, Endocarditis mortality, Female, France epidemiology, Heart Valve Diseases mortality, Heart Valve Diseases surgery, Heart Valve Prosthesis Implantation mortality, Heart Valve Prosthesis Implantation statistics & numerical data, Humans, Immunosuppression Therapy adverse effects, Male, Middle Aged, Prospective Studies, Treatment Outcome, Young Adult, Endocarditis surgery
- Abstract
Aims: To assess long-term outcomes and the management of critical left-sided infective endocarditis (IE) and evaluate the impact of surgery., Methods and Results: Among the 198 patients included prospectively for IE across 33 adult intensive care units (ICU) in France from 1 April 2007 to 1 October 2008, 137 (69%) were dead at a median follow-up time of 59.5 months. Characteristics significantly associated with mortality were: Sepsis-related Organ-Failure Assessment (SOFA) score at ICU admission [Hazard ratio (HR), 95% Confidence Interval (CI) of 1.43 (0.79-2.59) for SOFA 5-9; 2.01 (1.05-3.85) for SOFA 10-14; 3.53 (1.75-7.11) for SOFA 15-20; reference category SOFA 0-4; P = 0.003]; prosthetic mechanical valve IE [HR 2.01; 95% CI 1.09-3.69, P = 0.025]; vegetation size ≥15 mm [HR 1.64; 95% CI 1.03-2.63, P = 0.038]; and cardiac surgery [HR (95%CI), 0.33 (0.16-0.67) for surgery ≤1 day after IE diagnosis; 0.61 (0.29-1.26) for surgery 2-7 days after IE diagnosis; 0.42 (0.21-0.83) for surgery >7 days after IE diagnosis; reference category no surgery; P = 0.005]. One hundred and three (52%) patients underwent cardiac surgery after a median time of 6 (16) days. Independent predictors of surgical intervention on multivariate analysis were: age ≤60 years [Odds ratio (OR) 5.30; 95% CI (2.46-11.41), P < 0.01], heart failure [OR 3.27; 95% CI (1.03-10.35), P = 0.04], cardiogenic shock [OR 3.31; 95% CI (1.47-7.46), P = 0.004], septic shock [OR 0.25; 95% CI (0.11-0.59), P = 0.002], immunosuppression [OR 0.15; 95% CI (0.04-0.55), P = 0.004], and diagnosis before or within 24 h of ICU admission [OR 2.81; 95% CI (1.14-6.95), P = 0.025]. SOFA score calculated the day of surgery was the only independently associated factor with long-term mortality [HR (95% CI) 1.59 (0.77-3.28) for SOFA 5-9; 3.56 (1.71-7.38) for SOFA 10-14; 11.58 (4.02-33.35) for SOFA 15-20; reference category SOFA 0-4; P < 0.0001]. Surgical timing was not associated with post-operative outcomes. Of the 158 patients with a theoretical indication for surgery, the 58 deemed not fit had a 95% mortality rate., Conclusion: Mortality in patients with critical IE remains unacceptably high. Factors associated with long-term outcomes are the severity of multiorgan failure, prosthetic mechanical valve IE, vegetation size ≥15 mm, and surgical treatment. Up to one-third of potential candidates do not undergo surgery and these patients experience extremely high mortality rates. The strongest independent predictor of post-operative mortality is the pre-operative multiorgan failure score while surgical timing does not seem to impact on outcomes.
- Published
- 2014
- Full Text
- View/download PDF
26. Profile of the risk of death after septic shock in the present era: an epidemiologic study.
- Author
-
Pavon A, Binquet C, Kara F, Martinet O, Ganster F, Navellou JC, Castelain V, Barraud D, Cousson J, Louis G, Perez P, Kuteifan K, Noirot A, Badie J, Mezher C, Lessire H, Quantin C, Abrahamowicz M, and Quenot JP
- Subjects
- APACHE, Age Factors, Aged, Body Mass Index, Comorbidity, Cross Infection epidemiology, Female, Hospital Mortality, Humans, Male, Middle Aged, Organ Dysfunction Scores, Proportional Hazards Models, Prospective Studies, Risk Assessment, Sex Factors, Shock, Septic mortality, Intensive Care Units, Shock, Septic epidemiology
- Abstract
Objectives: To investigate mortality of ICU patients over a 3-month period after an initial episode of septic shock and to identify factors associated with mortality., Design: Prospective multicenter observational cohort study., Setting: Fourteen ICUs from 10 French nonacademic and university teaching hospitals., Patients: All consecutive adult patients with septic shock admitted between October 2009 and September 2011 were eligible., Intervention: None., Measurements and Main Results: Multivariable analyses were performed using a Cox proportional hazard model and a flexible extension of the Cox model. In total, 1,495 of 10,941 patients (13.7%) had septic shock and 1,488 patients (99.5%) were included. Median age was 68 years (range, 58-78 yr). The majority of admissions (84%) were medical. Median (interquartile range) Simplified Acute Physiological Score II and Sequential Organ Failure Assessment were, respectively, 56 (45-70) and 11 (9-14). ICU and hospital mortality were, respectively, 39.4% and 48.6%. At 3 months, 776 patients (52.2%) had died. Factors significantly associated with increased risk of death in the multivariable Cox model were older age, male sex, comorbidities (immune deficiency, cirrhosis), Knaus C/D score, and high Sequential Organ Failure Assessment score. Flexible analyses indicated that the impact of Sequential Organ Failure Assessment score was greatest early after septic shock, while the onset of the effect of age, nosocomial infection, and cirrhosis was later., Conclusions: This is the most recent large-scale epidemiological study to investigate medium-term mortality in nonselected patients hospitalized in the ICU for septic shock. Advances in early management have improved survival at the initial phase, but risk of death persists in the medium term. Flexible modeling techniques yield insights into the profile of the risk of death in the first 3 months.
- Published
- 2013
- Full Text
- View/download PDF
27. Enterocyte damage in critically ill patients is associated with shock condition and 28-day mortality.
- Author
-
Piton G, Belon F, Cypriani B, Regnard J, Puyraveau M, Manzon C, Navellou JC, and Capellier G
- Subjects
- Aged, Biomarkers blood, Citrulline blood, Confidence Intervals, Fatty Acid-Binding Proteins blood, Female, Hospital Mortality, Hospitals, University, Humans, Intensive Care Units, Intestine, Small physiopathology, Logistic Models, Male, Middle Aged, Odds Ratio, Prognosis, Prospective Studies, Shock mortality, Critical Illness, Enterocytes pathology, Shock pathology
- Abstract
Objectives: Small bowel dysfunction in critically ill patients is frequent, underdiagnosed, and associated with poor prognosis. Intestinal fatty acid-binding protein is a marker of enterocyte damage, and plasma citrulline concentration is a marker of functional enterocyte mass. Primary objective was to identify factors associated with intestinal fatty acid-binding protein in critically ill patients. Secondary objectives were to study factors associated with plasma citrulline concentration and its correlation with intestinal fatty acid-binding protein., Design: Prospective observational study., Setting: ICU in a University Hospital, Patients: Critically ill patients 18 years old or older with an expected length of ICU stay 48 hours or more, without pregnancy, chronic small bowel disease, or chronic renal failure., Interventions: None., Measurements and Main Results: Plasma intestinal fatty acid-binding protein and citrulline concentrations, and variables relating to prognosis and treatment, were measured at admission to the ICU. One hundred and three patients were included. Intestinal fatty acid-binding protein elevation at admission to the ICU was associated with catecholamine support, higher lactate concentration, higher Sequential Organ Failure Assessment score, and higher international normalized ratio (all p≤0.001). Plasma citrulline concentration less than or equal to 10 μmol/L at admission to the ICU was associated with higher intra-abdominal pressure, higher plasma C reactive protein concentration, and more frequent antibiotic use (all p≤0.005). There was no correlation between plasma levels of intestinal fatty acid-binding protein and citrulline. At ICU admission, Sequential Organ Failure Assessment score≥12, plasma citrulline≤12.2 μmol/L, and plasma intestinal fatty acid-binding protein concentration≥355 pg/mL were all independently associated with 28-day mortality (odds ratio, 4.39 [1.48-13.03]; odds ratio, 5.17 [1.59-16.86]; and odds ratio, 4.46 [1.35-14.74], respectively)., Conclusions: In critically ill patients, enterocyte damage is frequent, and it is significantly associated with shock and 28-day mortality. The link between intestinal fatty acid-binding protein and plasma citrulline concentrations in critically ill patients needs to be further evaluated.
- Published
- 2013
- Full Text
- View/download PDF
28. The epidemiology of septic shock in French intensive care units: the prospective multicenter cohort EPISS study.
- Author
-
Quenot JP, Binquet C, Kara F, Martinet O, Ganster F, Navellou JC, Castelain V, Barraud D, Cousson J, Louis G, Perez P, Kuteifan K, Noirot A, Badie J, Mezher C, Lessire H, and Pavon A
- Subjects
- Aged, Aged, 80 and over, Cohort Studies, Female, Follow-Up Studies, France epidemiology, Humans, Intensive Care Units, Male, Middle Aged, Mortality trends, Prospective Studies, Shock, Septic mortality, Shock, Septic diagnosis, Shock, Septic epidemiology
- Abstract
Introduction: To provide up-to-date information on the prognostic factors associated with 28-day mortality in a cohort of septic shock patients in intensive care units (ICUs)., Methods: Prospective, multicenter, observational cohort study in ICUs from 14 French general (non-academic) and university teaching hospitals. All consecutive patients with septic shock admitted between November 2009 and March 2011 were eligible for inclusion. We prospectively recorded data regarding patient characteristics, infection, severity of illness, life support therapy, and discharge., Results: Among 10,941 patients admitted to participating ICUs between October 2009 and September 2011, 1,495 (13.7%) patients presented inclusion criteria for septic shock and were included. Invasive mechanical ventilation was needed in 83.9% (n=1248), inotropes in 27.7% (n=412), continuous renal replacement therapy in 32.5% (n=484), and hemodialysis in 19.6% (n=291). Mortality at 28 days was 42% (n=625). Variables associated with time to mortality, right-censored at day 28: age (for each additional 10 years) (hazard ratio (HR)=1.29; 95% confidence interval (CI): 1.20-1.38), immunosuppression (HR=1.63; 95%CI: 1.37-1.96), Knaus class C/D score versus class A/B score (HR=1.36; 95%CI:1.14-1.62) and Sepsis-related Organ Failure Assessment (SOFA) score (HR=1.24 for each additional point; 95%CI: 1.21-1.27). Patients with septic shock and renal/urinary tract infection had a significantly longer time to mortality (HR=0.56; 95%CI: 0.42-0.75)., Conclusion: Our observational data of consecutive patients from real-life practice confirm that septic shock is common and carries high mortality in general ICU populations. Our results are in contrast with the clinical trial setting, and could be useful for healthcare planning and clinical study design.
- Published
- 2013
- Full Text
- View/download PDF
29. Neurologic complications and outcomes of infective endocarditis in critically ill patients: the ENDOcardite en REAnimation prospective multicenter study.
- Author
-
Sonneville R, Mirabel M, Hajage D, Tubach F, Vignon P, Perez P, Lavoué S, Kouatchet A, Pajot O, Mekontso Dessap A, Tonnelier JM, Bollaert PE, Frat JP, Navellou JC, Hyvernat H, Hssain AA, Tabah A, Trouillet JL, and Wolff M
- Subjects
- Aged, Cohort Studies, Critical Illness, Endocarditis mortality, Endocarditis therapy, Female, Humans, Male, Middle Aged, Retrospective Studies, Risk Factors, Survival Rate, Treatment Outcome, Endocarditis complications, Nervous System Diseases epidemiology, Nervous System Diseases microbiology
- Abstract
Objective: To describe the clinical spectrum of infective endocarditis in critically ill patients and assess the impact of neurologic complications on outcomes., Design: Prospective multicenter observational study conducted from April 2007 to October 2008., Setting: Thirty-three intensive care units in 23 university-affiliated and 10 general French hospitals., Patients: Two hundred twenty-five patients with definite IE were studied. Factors associated with neurologic complications and predictors of 3-month mortality were identified by logistic regression analysis. Functional outcomes of patients with neurologic complications were evaluated with the modified Rankin Scale., Interventions: None., Measurements and Main Results: Among 198 patients with definite left-sided infective endocarditis, 108 (55%) experienced at least one neurologic complication. These complications were ischemic stroke (n = 79), cerebral hemorrhage (n = 53), meningitis or meningeal reaction (n = 41), brain abscess (n = 14), and mycotic aneurysm (n = 10). Factors independently associated with neurologic complications were (subhazard ratio [95% confidence interval]): Staphylococcus aureus infective endocarditis (1.45 [1.02-2.05]), mitral valve infective endocarditis (1.54 [1.07-2.21]), and nonneurologic embolic events (1.51 [1.09-2.09]). In contrast, health care-associated infective endocarditis had a protective effect (0.46 [0.27-0.77]). Multivariate analysis identified three variables associated with 3-month mortality (odds ratio [95% confidence interval]): neurologic failure, as defined as a Glasgow Coma Scale <10 (7.41 [2.89-18.96]), S. aureus infective endocarditis (3.26 [1.53-6.94]), and severe comorbidities before admission as defined as a Charlson score >2 (3.16 [1.47-6.77]). Among the 106 patients with neurologic complications assessed at follow-up (3.9 [3-8.5] months), 31 (29%) had a modified Rankin Scale score ≤3 (ability to walk without assistance), nine (9%) a modified Rankin Scale score of 4 or 5 (severe disability), and 66 (62%) a modified Rankin Scale score of 6 (death)., Conclusions: Neurologic events are the most frequent complications in infective endocarditis patients requiring intensive care unit admission. They contribute to a severe prognosis, leaving less than one-third of patients alive with functional independence. Neurologic failure at intensive care unit admission represents a major determinant of mortality regardless of the underlying neurologic complication.
- Published
- 2011
- Full Text
- View/download PDF
30. Prone position and recruitment manoeuvre: the combined effect improves oxygenation.
- Author
-
Rival G, Patry C, Floret N, Navellou JC, Belle E, and Capellier G
- Subjects
- Aged, Blood Gas Analysis, Humans, Middle Aged, Oxygen chemistry, Prospective Studies, Supine Position physiology, Treatment Outcome, Positive-Pressure Respiration methods, Prone Position physiology, Respiratory Distress Syndrome physiopathology, Respiratory Distress Syndrome therapy
- Abstract
Introduction: Among the various methods for improving oxygenation while decreasing the risk of ventilation-induced lung injury in patients with acute respiratory distress syndrome (ARDS), a ventilation strategy combining prone position (PP) and recruitment manoeuvres (RMs) can be practiced. We studied the effects on oxygenation of both RM and PP applied in early ARDS patients., Methods: We conducted a prospective study. Sixteen consecutive patients with early ARDS fulfilling our criteria (ratio of arterial oxygen partial pressure to fraction of inspired oxygen (PaO2/FiO2) 98.3 ± 28 mmHg; positive end expiratory pressure, 10.7 ± 2.8 cmH2O) were analysed. Each patient was ventilated in both the supine position (SP) and the PP (six hours in each position). A 45 cmH2O extended sigh in pressure control mode was performed at the beginning of SP (RM1), one hour after turning to the PP (RM2) and at the end of the six-hour PP period (RM3)., Results: The mean arterial oxygen partial pressure (PaO2) changes after RM1, RM2 and RM3 were 9.6%, 15% and 19%, respectively. The PaO2 improvement after a single RM was significant after RM3 only (P < 0.05). Improvements in PaO2 level and PaO2/FiO2 ratio were transient in SP but durable during PP. PaO2/FiO2 ratio peaked at 218 mmHg after RM3. PaO2/FiO2 changes were significant only after RM3 and in the pulmonary ARDS group (P = 0.008). This global strategy had a benefit with regard to oxygenation: PaO2/FiO2 ratio increased from 98.3 mmHg to 165.6 mmHg 13 hours later at the end of the study (P < 0.05). Plateau airway pressures decreased after each RM and over the entire PP period and significantly after RM3 (P = 0.02). Some reversible side effects such as significant blood arterial pressure variations were found when extended sighs were performed., Conclusions: In our study, interventions such as a 45 cmH2O extended sigh during PP resulted in marked oxygenation improvement. Combined RM and PP led to the highest increase in PaO2/FiO2 ratio without major clinical side effects.
- Published
- 2011
- Full Text
- View/download PDF
31. Acute ischemic pancreatitis following cardiac arrest: a case report.
- Author
-
Piton G, Barbot O, Manzon C, Moronval F, Patry C, Navellou JC, Belle E, and Capellier G
- Subjects
- Acute Disease, Heart Arrest diagnostic imaging, Humans, Ischemia diagnostic imaging, Male, Middle Aged, Pancreas diagnostic imaging, Pancreas pathology, Pancreatitis diagnostic imaging, Radiography, Abdominal, Tomography, X-Ray Computed, Heart Arrest complications, Ischemia etiology, Pancreas blood supply, Pancreatitis etiology
- Abstract
Context: Ischemia is an established cause of acute pancreatitis; however, acute pancreatitis has never been reported after cardiac arrest., Case Report: We report a case of acute pancreatitis following cardiac arrest with prolonged cardiopulmonary resuscitation in a 58-year-old man, the mechanism of which is likely to be ischemic. The patient developed severe ischemic encephalopathy, leading to death. Possible causes of acute pancreatitis in a context of cardiopulmonary resuscitation are discussed., Conclusion: In case of abdominal distension following cardiac arrest, diagnoses of mesenteric ischemia and acute ischemic pancreatitis should be considered. Such digestive complications occurring after cardiac arrest probably reflect the severity of the ischemia.
- Published
- 2010
32. Plasma citrulline kinetics and prognostic value in critically ill patients.
- Author
-
Piton G, Manzon C, Monnet E, Cypriani B, Barbot O, Navellou JC, Carbonnel F, and Capellier G
- Subjects
- Biomarkers blood, Chi-Square Distribution, Citrulline pharmacokinetics, Enterocytes metabolism, Enterocytes pathology, Humans, Intestine, Small metabolism, Intestine, Small pathology, Logistic Models, Middle Aged, Predictive Value of Tests, Prognosis, Prospective Studies, Citrulline blood, Critical Illness, Hospital Mortality, Multiple Organ Failure blood, Multiple Organ Failure mortality
- Abstract
Purpose: Multiple organ failure is a leading cause of death in critically ill patients and could be secondary to early gut ischemia. Plasma citrulline is a biomarker of enterocyte mass, and critically ill patients may have enterocyte mass reduction. The objectives of this study were to assess plasma citrulline kinetics and its prognostic value in critically ill patients., Methods: This prospective observational study included adults without small bowel disease and without chronic renal failure consecutively admitted to a single intensive care unit. Prognostic variables as well as plasma citrulline concentrations were studied at admission, 12, 24, 48 h, and the 7th day after admission. Univariate and multivariate analyses including plasma citrulline (0-10, 11-20, and >20 micromol l(-1)) and other variables were performed., Results: Sixty-seven patients were included, and the 28-day mortality was 34%. During the 1st day mean plasma citrulline decreased from 18.8 to 13.5 micromol l(-1). Low plasma citrulline at 24 h was associated with low plasma glutamine and arginine (p = 0.01 and 0.04), and high plasma CRP concentration, nosocomial infection rate, and 28-day mortality (p = 0.008, 0.03, and 0.02, respectively). In multivariate analysis plasma citrulline < or = 10 micromol l(-1) at 24 h and SOFA score > or =8 at 24 h were associated with 28-day mortality(odds ratios 8.70 and 15.08)., Conclusions: In critically ill patients, low plasma citrulline at 24 h is an independent factor of mortality and could be a marker of acute intestinal failure.
- Published
- 2010
- Full Text
- View/download PDF
33. [Is surveillance of Pseudomonas aeruginosa carriage in intensive care units useful?].
- Author
-
Slekovec C, Navellou JC, Blasco G, Thouverez M, Bertrand X, and Talon D
- Subjects
- Critical Care, Cross Infection microbiology, Cross Infection prevention & control, Humans, Predictive Value of Tests, Retrospective Studies, Carrier State diagnosis, Carrier State microbiology, Intensive Care Units organization & administration, Pseudomonas Infections diagnosis, Pseudomonas Infections microbiology, Pseudomonas aeruginosa
- Abstract
Objective: To evaluate the potential interest of screening of Pseudomonas aeruginosa on admission and during hospitalisation in intensive care units patients., Method: A retrospective study was carried out in two adult ICU of the University-Hospital of Besançon in 2007. P. aeruginosa screening was performed on admission and once a week during ICU stay. Clinical samples positive with P. aeruginosa were collected., Results: Among the 754 patients included, 146 had a screening sample positive giving an average incidence of 19.4 per 100 patients. Thirty-five were imported and 111 ICU-acquired. Sixty-one patients had at least one positive clinical sample, that is an incidence 8.1 cases per 100 admitted patients. Sensibility, specificity, positive and negative predictive values of screening as an indicator of subsequent infection were 54.1%, 86.9%, 26.6% and 95.6%, respectively., Conclusion: Screening samples are necessary to assess P. aeruginosa endemicity in intensive care units. The high negative predictive value of screening suggests that use of specifics anti-Pseudomonas antimicrobials could be reduced. However, the benefit of this strategy remains to be evaluated., (Copyright 2009 Elsevier Masson SAS. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
34. [Atypical sore throats].
- Author
-
Manzon C, Mesplede C, Navellou JC, Badet JM, and Capellier G
- Subjects
- Abscess microbiology, Adult, Female, Fusobacterium necrophorum, Humans, Male, Pharyngitis microbiology, Pleuropneumonia microbiology, Renal Insufficiency diagnosis, Abscess diagnosis, Fusobacterium Infections diagnosis, Jugular Veins, Pleuropneumonia diagnosis, Thrombosis diagnosis
- Published
- 2009
- Full Text
- View/download PDF
35. DRESS syndrome in a patient on sulfasalazine for rheumatoid arthritis.
- Author
-
Michel F, Navellou JC, Ferraud D, Toussirot E, and Wendling D
- Subjects
- Exanthema chemically induced, Female, Herpesvirus 6, Human, Humans, Middle Aged, Roseolovirus Infections complications, Antirheumatic Agents adverse effects, Arthritis, Rheumatoid drug therapy, Drug Eruptions etiology, Eosinophilia chemically induced, Sulfasalazine adverse effects
- Abstract
DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) is a drug-induced hypersensitivity syndrome that can mimic malignant lymphoma. We report a case in a 63-year-old woman who had been on sulfasalazine for 2 months to treat rheumatoid arthritis. She was admitted a few days after onset of a flu-like syndrome with a pruriginous maculopapular erythema initially involving the face, trunk, and proximal limbs; a fever of 41 degrees C; and enlargement of the liver, spleen, and several peripheral lymph nodes. Blood tests showed marked eosinophilia (9300/mm3), lymphocytosis, hyperbasophilic cells, and severe inflammation. DRESS syndrome was diagnosed. An indirect immunofluorescence assay for human herpesvirus 6 (HHV6) was positive, supporting recent HHV6 infection. Primary HHV6 infection and HHV6 reactivation have been incriminated in the genesis of DRESS syndrome. DRESS syndrome continues to carry a high mortality rate of about 10%. Drugs previously reported to cause DRESS syndrome include sulfasalazine, hydantoin, d-penicillamine, allopurinol, hydrochlorothiazide, and cyclosporine. A high index of suspicion for DRESS syndrome should be maintained in patients receiving these drugs. Serological tests for HHV6 should be performed routinely in patients with suspected DRESS syndrome, although uncertainty persists about the link between HHV6 infection and DRESS syndrome.
- Published
- 2005
- Full Text
- View/download PDF
36. [Involvement of thoracic aorta revealing temporal arteritis. Three cases].
- Author
-
Navellou JC, Gil H, Meaux-Ruault N, Magy N, Kantelip B, and Dupond JL
- Subjects
- Adrenal Cortex Hormones therapeutic use, Aged, Aortic Aneurysm pathology, Aortic Valve Insufficiency pathology, Diagnosis, Differential, Female, Giant Cell Arteritis surgery, Humans, Immunosuppressive Agents therapeutic use, Aorta, Thoracic pathology, Aortic Aneurysm etiology, Aortic Valve Insufficiency etiology, Giant Cell Arteritis complications, Giant Cell Arteritis diagnosis
- Abstract
Introduction: Temporal arteritis involves large vessels in 15% of cases. Their discovery is usually late, commonly several years after the diagnosis., Exegesis: We describe three cases of temporal arteritis with thoracic aorta involvement: two patients presented with aorta aneurysm which revealed temporal arteritis, one patient had aortic insufficiency. Clinical features of temporal arteritis were absent in two patients. Temporal artery biopsy, performed in two cases, was positive. Two patients were treated with corticosteroids, associated in one case with immunosuppressive agent. Surgery was necessary in all patients., Conclusion: Thoracic aorta involvement in Horton's disease is most often discovered when corticotherapy is decreased. Aneurysm rupture or aortic dissection in aortic affection are the major complication. Patient with thoracic aorta involvement need a clinical and radiological follow up over long period.
- Published
- 2004
- Full Text
- View/download PDF
37. [Long live springtime! My mother...it is not a trap...].
- Author
-
Dupond JL, Gil H, Navellou JC, Meaux N, Magy N, and Mahammedi H
- Subjects
- Female, Humans, Middle Aged, Parity, Seasons, Familial Mediterranean Fever diagnosis, Fever of Unknown Origin etiology
- Published
- 2002
- Full Text
- View/download PDF
38. [Chronic polyradiculoneuropathy in a patient with Hodgkin's disease].
- Author
-
Navellou JC, Michel F, Vuillier J, Toussirot E, and Wendling D
- Subjects
- Adult, Disease Progression, Electromyography, Humans, Magnetic Resonance Imaging, Male, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating diagnosis, Hodgkin Disease complications, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating etiology
- Published
- 2001
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.